DE69129332D1 - Behandlung von organtransplantatsabstossung - Google Patents

Behandlung von organtransplantatsabstossung

Info

Publication number
DE69129332D1
DE69129332D1 DE69129332T DE69129332T DE69129332D1 DE 69129332 D1 DE69129332 D1 DE 69129332D1 DE 69129332 T DE69129332 T DE 69129332T DE 69129332 T DE69129332 T DE 69129332T DE 69129332 D1 DE69129332 D1 DE 69129332D1
Authority
DE
Germany
Prior art keywords
treatment
transplant rejection
organ transplant
fluoro
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69129332T
Other languages
English (en)
Other versions
DE69129332T2 (de
Inventor
Neil Ackerman
Bruce Jaffee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Application granted granted Critical
Publication of DE69129332D1 publication Critical patent/DE69129332D1/de
Publication of DE69129332T2 publication Critical patent/DE69129332T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69129332T 1990-06-11 1991-06-05 Behandlung von organtransplantatsabstossung Expired - Fee Related DE69129332T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/535,672 US5204329A (en) 1990-06-11 1990-06-11 Treatment of organ transplantation rejection
PCT/US1991/003788 WO1991019498A1 (en) 1990-06-11 1991-06-05 Treatment of organ transplantation rejection

Publications (2)

Publication Number Publication Date
DE69129332D1 true DE69129332D1 (de) 1998-06-04
DE69129332T2 DE69129332T2 (de) 1998-08-27

Family

ID=24135268

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129332T Expired - Fee Related DE69129332T2 (de) 1990-06-11 1991-06-05 Behandlung von organtransplantatsabstossung

Country Status (14)

Country Link
US (1) US5204329A (de)
EP (1) EP0537191B1 (de)
JP (1) JPH05507697A (de)
KR (1) KR930700107A (de)
AT (1) ATE165511T1 (de)
AU (1) AU664354B2 (de)
CA (1) CA2085002A1 (de)
DE (1) DE69129332T2 (de)
DK (1) DK0537191T3 (de)
ES (1) ES2114888T3 (de)
IE (1) IE911962A1 (de)
IL (1) IL98425A (de)
WO (1) WO1991019498A1 (de)
ZA (1) ZA914456B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06116151A (ja) * 1991-08-06 1994-04-26 Asahi Chem Ind Co Ltd 増殖性皮膚疾患治療用組成物
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US5409886A (en) * 1993-02-18 1995-04-25 Mitsui Toatsu Chemicals, Incorporated 3-pyrroline-2-one derivatives and herbicidal compositions containing same
US6171585B1 (en) 1993-05-14 2001-01-09 Cedars-Sinai Medical Center IVIg immunosuppression in HLA-sensitized transplant recipients
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US5578609A (en) * 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
US5627193A (en) * 1995-02-09 1997-05-06 Mitsui Toatsu Chemicals, Inc. Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
WO1997042953A1 (en) * 1996-05-10 1997-11-20 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
AU757059B2 (en) 1997-06-19 2003-01-30 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
AU2108099A (en) * 1998-01-30 1999-08-16 Procept, Inc. Immunosuppressive agents
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US6608045B2 (en) * 1998-03-27 2003-08-19 Chong Kun Dang Corporation Streptomyces sp producing tautomycetin and immunosuppressant comprising tautomycetin as active ingredient
US7323471B1 (en) 1999-08-13 2008-01-29 Dor Biopharma, Inc. Topical azathioprine for the treatment of oral autoimmune diseases
AU2014352920A1 (en) 2013-11-22 2016-06-23 Genzyme Corporation Novel methods for treating neurodegenerative diseases
EP3102239A1 (de) * 2014-02-07 2016-12-14 Neurocrine Biosciences, Inc. Pharmazeutische zusammensetzungen mit antipsychotika und vmat2-inhibitor sowie verwendungen davon
WO2015120436A2 (en) * 2014-02-10 2015-08-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 phosphorylation during graft-versus-host disease
MA43116B1 (fr) 2015-10-30 2021-04-30 Neurocrine Biosciences Inc Ditosylate de valbénazine et polymorphes associés
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
KR20200066662A (ko) 2017-01-27 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EA202090932A1 (ru) 2017-10-10 2021-05-20 Нейрокрин Байосайенсиз, Инк Способы введения некоторых vmat2-ингибиторов
CA3104693A1 (en) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6592M (de) * 1967-10-31 1968-12-30
GB1334705A (en) * 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
CH567477A5 (de) * 1972-03-10 1975-10-15 Ciba Geigy Ag
DE2449030A1 (de) * 1974-10-11 1976-05-20 Schering Ag Neue pyridin-derivate
US4407803A (en) * 1981-08-17 1983-10-04 Abbott Laboratories Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
FI75308C (sv) * 1985-01-25 1988-06-09 Ky Carlson Project Kb Hydrostatiskt drivsystem.
US4625034A (en) * 1985-02-04 1986-11-25 Usv Pharmaceutical Corp. 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4661499A (en) * 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines
GB8602372D0 (en) * 1986-01-31 1986-03-05 Sandoz Ltd Organic compounds
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US4968701A (en) * 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
US4861783A (en) * 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
DE3814504A1 (de) * 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
WO1991019498A1 (en) 1991-12-26
JPH05507697A (ja) 1993-11-04
DE69129332T2 (de) 1998-08-27
DK0537191T3 (da) 1998-10-07
IE911962A1 (en) 1991-12-18
KR930700107A (ko) 1993-03-13
EP0537191A1 (de) 1993-04-21
IL98425A (en) 1995-06-29
ZA914456B (en) 1993-02-24
AU664354B2 (en) 1995-11-16
ATE165511T1 (de) 1998-05-15
EP0537191A4 (en) 1993-08-11
US5204329A (en) 1993-04-20
EP0537191B1 (de) 1998-04-29
ES2114888T3 (es) 1998-06-16
AU8087391A (en) 1992-01-07
CA2085002A1 (en) 1991-12-12

Similar Documents

Publication Publication Date Title
DE69129332D1 (de) Behandlung von organtransplantatsabstossung
TR199801919T2 (xx) Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE148469T1 (de) Zyklosporine
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
CY1110972T1 (el) Ανοσοκαταστολη με σαπερονινη 10
DE3884200D1 (de) Verfahren zur Behandlung von Mastitis und anderen Staphylokokkeninfektionen.
ATE87480T1 (de) 4-chinolincarbon-derivate, brauchbar als immuno- suppressive wirkstoffe.
SE9302431D0 (sv) Use of indenoindole compounds
AU8216691A (en) Autobiotics and their use in eliminating nonself cells in vivo
EA199900507A1 (ru) Способы профилактики отторжения трансплантата при трансплантации и продуцирования универсальной клетки-хозяина для генной терапии
FI931204A (fi) Nya, saosom lipooxigenasinhibitorer verkande aminobensosultamderivat
DE3875306T2 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
DE69125940T2 (de) Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
DE60045638D1 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
ES2052482T3 (es) Inhibidor de la proliferacion de celulas endoteliales.
BR9506838A (pt) Derivados de ácido micofenólico substituídos na posição 5
DK0379098T3 (da) Svovlholdige acrylsyreestere og fungicider indeholdende disse
RU97117419A (ru) Эндопротез голеностопного сустава
TR200103748T2 (tr) Organ nakli reddinin inhibe edilmesi için UK 114 proteinin kullanımı
FR2656199B1 (fr) Compositions fongicides ternaires pour le traitement du mildiou de la vigne.
ATE49958T1 (de) Pharmazeutische zusammensetzungen mit immunodepressivwirkung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DU PONT PHARMACEUTICALS CO., WILMINGTON, DEL., US

8339 Ceased/non-payment of the annual fee